Thursday, January 4, 2007 8:00:00 AM PDT | VentureDeal Staff
ROCKVILLE, MD -- CoGenesys, a Human Genome Sciences spinoff, has filed to begin human trials in Europe for its Neugranin drug. The drug is designed to treat patients with infections received as a result of chemotherapy drugs. The first test will dose patients about to undergo breast cancer chemotherapy. The company also recently launched human trials for Cardeva, its heart failure drug. It is also working on an insulin in earlier stages of development.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
